Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,043 mentions
- robotic manipulationmarket824 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology491 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology371 mentions
- agentic AItechnology353 mentions
- vision-language-action modeltechnology350 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Vision-Language Modeltechnology318 mentions
- Microsoftorganization291 mentions
- Googleorganization276 mentions
- NVIDIAorganization264 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology175 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology169 mentions
- IBMorganization163 mentions
Entity
Stargardt disease treatment
market6 mentionslast seen Nov 5, 2026
Treatment of Stargardt disease.
Relationships 1
Relationship
MOGENRYapplies toStargardt disease treatment
99% confidence4 supporting mentions
Either name opens that entity’s relationships.
Sources 4
- newsPR NewswireNov 5, 2026Nanoscope Therapeutics Appoints Ophthalmology and Rare Disease Regulatory Leader Damon Daulerio as Executive Director of Regulatory Affairs
STARLIGHT Phase 2 clinical trial (NCT05417126) of MCO-010 in Stargardt disease (SD)
- newsPR NewswireOct 29, 2026Nanoscope Therapeutics to Participate in Advanced Therapies USA 2026 in Boston
STARLIGHT Phase 2 clinical trial of MCO-010 in Stargardt disease (SD)
- newsPR NewswireOct 14, 2026Nanoscope Therapeutics Appoints Gene Therapy Operations Leader Troy Short as Senior Vice President, Manufacturing and Supply Chain
STARLIGHT Phase 2 clinical trial (NCT05417126) of MCO-010 in Stargardt disease (SD)
- newsPR NewswireSep 29, 2026Nanoscope Therapeutics to Present at Meeting on the Mesa 2026
shown promising results in the STARLIGHT Phase 2 clinical trial of MCO-010 in Stargardt disease (SD)